FORA.tv Speaker - Howard I. Scher
Howard I. Scher, MD is Chief of the Genitourinary Oncology Service at Memorial Sloan-Kettering Cancer Center and Professor of Medicine at the Weill Cornell Medical College. An internationally recognized investigator, Dr. Scher has helped elucidate key molecular and genetic features of prostate cancer and has translated these insights into the evaluation of novel targeted agents in the clinic. Most recently, he led the clinical development of enzalutamide (MDV3100), a novel androgen-receptor signaling inhibitor targeting a key driver of prostate cancer growth. His work also focuses on developing non-invasive methods of determining whether targeted therapies are working.
Dr. Scher is a member of the Prostate Cancer Clinical Trials Working Group and led an international effort to standardize the design and analysis of phase II trials. He is also principal investigator of the NIH-supported Specialized Program of Research Excellence (SPORE) in Prostate Cancer and the Prostate Cancer Clinical Trials Consortium, a multi-center research collaborative funded by the Department of Defense and the Prostate Cancer Foundation.
Dr. Scher is widely published, the recipient of numerous awards, and the first incumbent of the D. Wayne Calloway Chair in Urologic Oncology.
11.15.12 | 00:47:00 min
| 0 comments